For those suffering from rare diseases, you got a friend in Amicus Therapeutics

Based in Cranbury, New Jersey, Amicus Therapeutics is an American company that deals with biopharmaceuticals. The firm has developed advanced therapies to address rare and orphan diseases. Having gone public with its IPO in 2006 at NASDAQ Stock Exchange, the company has over the years developed a spectrum of treatment approached to address a variety of devastating human genetic problems.

With ATB200/AT2221 as their forefront biologics, which is a uniquely designed intervention for Pompe disease and applied alongside a pharmacological chaperone, Amicus Therapeutics has carved out a niche in the field of treating orphan diseases.

Migalastat, one of the company’s most robust interventions, is designed as an intervention for individuals suffering from late stages of Fabry disease in line with the patient’s genetic diagnosis. Another product candidate for late-stage development, SD-101, is a potential milestone therapy, the first-of-its-kind to treat the not so common connective tissue disease Epidermolysis Bullosa. Taking advantage of their biologics and utilizing the platform technologies of the Brandy Chaperone Advance Replacement Therapy, abbreviated as CHART, to develop new Enzyme Replacement Therapy interventions for the Pompe disease, Fabry disease, and similar lysosomal storage disorders. Know more on gcreport.com about Amicus Therapeutics.

Amicus Therapeutics got praised in 2004 as having possibly the broadest and most advanced portfolio of small molecules category of pharmacological chaperones. It was in 2008 when the company made a significant milestone in opening a new research center in San Diego to add to the one at New Jersey. Five years later Amicus would effect the acquisition of a rival company Callidus Biopharma which was a significant breakthrough especially in the development of the enzyme therapy intervention for the Pompe disease.

Read: https://www.indeed.com/q-Amicus-Therapeutics-l-Cranbury,-NJ-jobs.html

For 947 million dollars, the firm would acquire another of its competitors less than two years later, further advancing its dominance in the sector. John F. Crowley is both the CEO and the chairman of the board. Follow Amicus Therapeutics on Twitter.